论文部分内容阅读
目的探讨吡格列酮对波动性高糖处理的人脐静脉内皮细胞(HUVEC)脂联素受体(AdipoR1和AdipoR2)表达的影响。方法将HUVEC在波动性高糖培养液(5.5、20mmol.L-1每隔8h轮换1次)中培养5d后,随机分为阴性对照组、吡格列酮处理组(10、1与0.1μmol.L-1)和阳性对照组。应用实时定量PCR方法检测脂联素受体mRNA表达的改变。结果与波动性高糖组比较,吡格列酮处理后HU-VECAdipoR1表达增高。当吡格列酮浓度增至1μmol.L-1以上时,AdipoR1mRNA表达增加呈现差异。各组细胞Adi-poR2表达量间差别无显著性。结论AdipoR1很可能是胰岛素增敏剂吡格列酮改善内皮胰岛素敏感性的作用机制之
Objective To investigate the effect of pioglitazone on the expression of adiponectin receptor (AdipoR1 and AdipoR2) in human umbilical vein endothelial cells (HUVEC) treated with high glucose. Methods HUVECs were cultured in fluctuating high glucose medium (5.5,20 mmol.L-1 once every 8h) for 5 days and then randomly divided into negative control group, pioglitazone treatment group (10, 1 and 0.1μmol.L- 1) and positive control group. Real-time quantitative PCR was used to detect the change of adiponectin receptor mRNA expression. Results Compared with the high glucose group, the expression of HU-VECAdipoR1 increased after pioglitazone treatment. When the concentration of pioglitazone increased above 1μmol.L-1, the expression of AdipoR1mRNA increased. There was no significant difference in the expression of Adi-poR2 in each group. Conclusion AdipoR1 is likely to be the mechanism by which insulin sensitizer pioglitazone improves endothelial insulin sensitivity